Revita
Revita DMR System Target: duodenal mucosa
Fractyl Health
Most recent annual filing: 2026-01-15
- Rejuva readout2H 2026Rejuva readout, 2H 2026, notable
- RJVA-001 corporate update2H 2026RJVA-001 corporate update, 2H 2026, routine
- Corporate guidance updateSep 2026Corporate guidance update, Sep 2026, routine
- Revita pivotal topline4Q 2026Revita pivotal topline, 4Q 2026, thesis-defining
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (3 active programs)
Technology platforms
Rejuva
AAV-delivered pancreatic gene therapy platform designed to enable long-term remission of T2D and obesity by durably reprogramming pancreatic islet cells to endogenously produce metabolic hormones (GLP-1, GIP, PYY, amylin, glucagon). Modular platform using AAV9 vectors with tissue-restricted insulin promoter-driven transgene expression, delivered via proprietary endoscopic device directly to the pancreas.
Targets: GLP-1, GIP, PYY, amylin
Discontinued (1)
- Revita — Type 2 Diabetes · Strategic Reprioritization announced January 31, 2025; investment in Revita for T2D paused including REVITALIZE-1 study
Biotech Distilled coverage (8)
- 2026-08-11 UPDATE: Fractyl Health (GUTS) - The Going Concern Arrives
- 2026-07-15 UPDATE: Fractyl Health (GUTS) - The Durability Question, Answered (Randomized Edition) 🔒 Paid
- 2026-06-04 UPDATE: Fractyl Health (GUTS) - The Durability Question, Answered
- 2026-05-12 UPDATE: Fractyl Health (GUTS) - The Moonshot Gets a Clinic 🔒 Paid
- 2026-03-29 UPDATES: Fractyl Health (GUTS) - Insiders Buys 🔒 Paid
- 2026-02-28 UPDATE: Fractyl Health (GUTS) - The Clock is Set 🔒 Paid
- 2026-01-30 UPDATE: Fractyl Health (GUTS) - The Mixed Data Crash (6-Mo Readout) 🔒 Paid
- 2026-01-07 Fractyl Health (GUTS): Scientific Deep Dive for Revita® and Rejuva®
Articles open on Substack. Some deep dives are subscriber-only.